Star Combo Pharma Ltd. · ASX:S66
Star Combo Pharma — Shareholder Meeting (November 2024)
17 slides from Star Combo Pharma's shareholder meeting presentation, Nov 26, 2024
Slide 1: Star Combo 2024 AGM – CEO Presentation (ASX announcement)
STAR COMBO PHARMA LTD ABN 38 615 728 375 171 -177 Woodpark Rd Smithfield NSW 2164 P: +61 2 9756 6555 sales@starcombo.com.au 26 November 2024 ASX Announcement Star Combo 2024 AGM – CEO Presentation ____________________________________________________________________________________ Attached, please f
Slide 2: CEO Presentation – Annual General Meeting
Su Zhang For personal use only Chief Executive Officer CEO Presentation STAR COMBO PHARMA LIMITED Annual General Meeting 26 November 2024 1
Slide 3: FY24 Key results
FY24 Key results For personal use only Group Revenue increased by 5.3% year on year and Group Profit Before Asset write down increased by 4.6% year on year Record OEM Revenue OEM production efficiencies Retail Division returns to small full year profit Strong cash position at 30 June 2024
Slide 4: FY Group Financial Performance
FY 24 Group Financial Performance For personal use only FY24 FY23 FY22 $000’s $000’s $000’s Note 1 OEM Revenue $23,400 $20,729 $16,177 Retail Revenue $2,660 $3,947 $6,672 Group Revenue $26,019 $24,700 $22,880 Profit/(Loss) Before Tax $1,001 ($3,454) ($1,081) Profit before asset write down $1,001 $95
Slide 5: OEM Division record Revenue
OEM Division record Revenue FY 24 FY 23 FY 22 For personal use only Full Year Full Year Full Year $000’s $000’s $000’s External Sales $23,342.7 $20,729.7 $16,177.3 Profit from Operations $1,235.0 $1,303.9 $1,489.8 Asset Impairment Note ($4,412.7) Depreciation and Amortisation ($275.9) ($125.4) ($453
Slide 6: OEM Division Update
OEM Division Update Manufacturing Division (OEM and Branded) For personal use only OEM division has again performed strongly with increasing volume of bulk orders manufactured for new customers 34 new customer accounts have been established in the last twelve months. At the date of this report
Slide 7: OEM Production efficiencies
OEM Production efficiencies +/(-)% FY 2024 FY 2023 For personal use only YOY Capsules/Tablets Manufactured 519,052,811 0% 520,767,220 Batches Manufactured 335 9% 306 Actual Production Time – Hrs 59,715 -6% 63,342 Potential Production Time - Hrs 78,489 -7% 84,456 Production OEE 76.08% 1% 75.00% 6
Slide 8: Building Improvements
Building Improvements Building 1 (main manufacturing facility and commercial offices) For personal use only Continues to be well maintained to a high standard. Building 2 (subject of the fire in October 2022). has been made safe and limited manufacturing capacity re-instated Building 3 – (
Slide 9: Retail Division returns to Profit
Retail Division returns to Profit FY 24 FY 23 FY 22 For personal use only Full Year Full Year Full Year $000’s $000’s $000’s External Sales $2,660.6 $3,947.2 $6,672.8 Profit/(Loss) from Operations $41.9 ($216.7) ($613.3) Asset Impairment Note ($1,459.4) Depreciation and Amortisation ($4.1) ($45.7) P
Slide 10: Retail Division Update
Retail Division Update The retail division was significantly impacted by the COVID pandemic and has required some significant For personal use only restructuring and impairment of assets in FY23. Physical retail stores that the business operated in Carlingford and Ashfield in Sydney were closed
Slide 11: Cash Position
Cash Position Strong cash position at 30 June 2024 2024 2023 For personal use only $M's $M's Full year cash flow: Cash and Cash Equivalents at beginning of Year $9.49 $10.39 Less Capital Expenditure ($1.44) ($2.73) Changes in Working Capital $0.31 $1.82 Cash and Cash Equivalents at end of Year $8.36
Slide 12: FY25 Q1
FY25 Q1 For personal use only During FY2025 the Group is continuing its focus on implementing and transitioning its strategy to become a leading contract manufacturer in Australia for the vitamin and health supplements sector. OEM production increases OEM Revenue grows Retail Division contin
Slide 13: Group Revenue Q1 FY25
Group Revenue Q1 FY25 For personal use only FY25 Q1 FY24 Q1 $000’s $000’s Note 1 OEM Revenue $8,395 $6,075 Retail Revenue $489 $759 Group Revenue $8,885 $6,834 Profit/(Loss) Before Tax $666 $568 Note 1 Unaudited three months trading to end Sept 12
Slide 14: Our people
Our people For personal use only People Safety Well being Our team have demonstrated As a manufacturing business, A comprehensive WHS plan agility and tenacity in guiding we are dedicated to ensuring has been implemented at the business through the we have a safe workplace. Star Combo. unfortunate f
Slide 15: Achievements & Outlook
Achievements & Outlook For personal use only FY24 Continued growth in contract Operating cash flow positive Retail Business restructured Achievements manufacturing division with $8.3M in cash in bank Contract manufacturing 2025 Contract manufacturing sector remains main area of outlook remains resil
Slide 16: Thank You
Investor relations For personal use only investors@starcombo.com.au THANK YOU 10
Slide 17: Disclaimer
DISCLAIMER The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Commission (ASIC). This pr
Star Combo Pharma — Shareholder Meeting (November 2024) on 6ix